2,3-Diarylpropenoic acids as selective non-steroidal inhibitors of type-5 17β-hydroxysteroid dehydrogenase (AKR1C3)

European Journal of Medicinal Chemistry

Volumn 62, Issue , 2013, Pages 89-97

  Gazvoda, Martin ^a   Beranič, Nataša ^a   Turk, Samo ^a   Burja, Bojan ^a   Kočevar, Marijan ^a   Rižner, Tea Lanišnik ^a   Gobec, Stanislav ^a   Polanc, Slovenko ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

2,3 Diarylpropenoic acids; AKR1C3; Aldo keto reductase; Cancer; Selective inhibitors

Indexed keywords

3 (4 BROMOPHENYL) 2 [4 (METHYLSULFONYL)PHENYL]PROP 2 ENOIC ACID; 3 (4 ETHYLPHENYL) 2 [4 (METHYLSULFONYL)PHENYL]PROP 2 ENOIC ACID; 3 (4 METHYLPHENYL) 2 [4 (METHYLSULFONYL)PHENYL]PROP 2 ENOIC ACID; 3 [4 (METHYLSULFANYL)PHENYL] 2 [4 (METHYLSULFONYL)PHENYL]PROP 2 ENOIC ACID; ACRYLIC ACID DERIVATIVE; TESTOSTERONE 17BETA DEHYDROGENASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BREAST CANCER; DRUG SELECTIVITY; HUMAN; MOLECULAR DOCKING; PROSTATE CANCER;

3-HYDROXYSTEROID DEHYDROGENASES; ACRYLATES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PHENYLPROPIONATES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84872677883     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2012.12.045     Document Type: Article

References (35)

1. T.M. Penning, M.E. Burczynski, J.M. Jez, C.F. Hung, H.K. Lin, H. Ma, M. Moore, N. Palackal, and K. Ratnam Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones Biochem. J. 351 2000 67 77
2. T.M. Penning, and M.C. Byrns Steroid hormone transforming aldo-keto reductases and cancer Ann. N. Y. Acad. Sci. 1155 2009 33 42
3. T.M. Penning, and J.E. Drury Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms Arch. Biochem. Biophys. 464 2007 241 250
4. I. Dufort, P. Rheault, X.F. Huang, P. Soucy, and V. Luu-The Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase Endocrinology 140 1999 568 574
5. M.C. Byrns, L. Duan, S.H. Lee, I.A. Blair, and T.M. Penning Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer J. Steroid Biochem. Mol. Biol. 118 2010 177 187
6. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
7. T. Lanišnik-Rižner, T. Šmuc, R. Rupreht, J. Šinkovec, and T.M. Penning AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer Mol. Cell. Endocrinol. 248 2006 126 135
8. T. Šmuc, N. Hevir, M. Ribič-Pucelj, B. Husen, H. Thole, and T.L. Rižner Disturbed estrogen and progesterone action in ovarian endometriosis Mol. Cell. Endocrinol. 301 2009 59 64
9. P. Brožič, S. Turk, T.L. Rižner, and S. Gobec Inhibitors of aldo-keto reductases AKR1C1-AKR1C4 Curr. Med. Chem. 18 2011 2554 2565
10. M.C. Byrns, Y. Jin, and M.P. Penning Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights J. Steroid Biochem. Mol. Biol. 125 2011 95 104
11. N. Beranič, S. Gobec, and T.L. Rižner Progestins as inhibitors of the human 20-ketosteroid reductases, AKR1C1 and AKR1C3 Chem. Biol. Interact. 191 2011 227 233
12. P. Bydal, V. Luu-The, F. Labrie, and D. Poirier Steroidal lactones as inhibitors of 17β-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities Eur. J. Med. Chem. 44 2009 632 644
13. B. Štefane, P. Brožič, M. Vehovc, T.L. Rižner, and S. Gobec New cyclopentane derivatives as inhibitors of steroid metabolizing enzymes AKR1C1 and AKR1C3 Eur. J. Med. Chem. 44 2009 2563 2571
14. Y. Higaki, N. Usami, S. Shintani, S. Ishikura, O. El-Kabbani, and A. Hara Selective and potent inhibitors of human 20α-hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone Chem. Biol. Interact. 143-144 2003 503 513
15. L. Skarydova, L. Zivna, G. Xiong, E. Maser, and V. Wsol AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids Chem. Biol. Interact. 178 2009 138 144
16. P. Brožič, B. Golob, N. Gomboc, T. Lanišnik- Rižner, and S. Gobec Cinnamic acids as new inhibitors of 17β-hydroxysteroid dehydrogenase type 5 (AKR1C3) Mol. Cell. Endocrinol. 248 2006 233 235
17. S. Endo, T. Matsunaga, A. Kanamori, Y. Otsuji, H. Nagai, K. Sundaram, O. El-Kabbani, N. Toyooka, S. Ohta, and A. Hara Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of brazilian propolis J. Nat. Prod. 75 2012 716 721
18. N.J. Davies, R.E. Hayden, P.J. Simpson, J. Birtwistle, K. Mayer, J.P. Ride, and C.M. Bunce AKR1C isoforms represent a novel cellular target for jasmonates alongside their mitochondrial-mediated effects Cancer Res. 69 2009 4769 4775
19. M.C. Byrns, S. Steckelbroeck, and T.M. Penning An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3α-HSD, type 5 17β-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies Biochem. Pharmacol. 75 2008 484 493
20. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, J.D. Winkler, and T.M. Penning Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) Bioorg. Med. Chem. Lett. 21 2011 1464 1468
21. A.O. Adeniji, B.M. Twenter, M.C. Byrns, Y. Jin, M. Chen, J.D. Winkler, and T.M. Penning Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships J. Med. Chem. 55 2012 2311 2323
22. S. Li, W. Yuan, and S. Ma Highly regio- and stereoselective three-component nickel-catalyzed syn-hydrocarboxylation of alkynes with diethyl zinc and carbon dioxide Angew. Chem. Int. Ed. 50 2011 2578 2582
23. B. Burja, T. Čimbora-Zovko, S. Tomić, T. Jelušić, M. Kočevar, S. Polanc, and M. Osmak Pyrazolone-fused combretastatins and their precursors: synthesis, cytotoxicity, antitubulin activity and molecular modeling studies Bioorg. Med. Chem. 18 2010 2375 2387
24. A. Moreau, O.-H. Chen, P.N.P. Rao, and E.E. Knaus Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases Bioorg. Med. Chem. 14 2006 7716 7727
25. C. Zhu, Y. Zhang, G. Cao, S. Peng, W. Wang, and J. Zheng Studies on the nonsteroidal antifertility agents. II. Synthesis and antifertility activity of some p-coumaric acid derivatives Nanjing Yaoxueyuan Xuebao 1982 50 56 Chem. Abstr. 99 (1983) 212230
26. J.J. Talley, J.S. Carter, P.W. Collins, S.W. Kramer, T.D. Penning, D.J. Rogier Jr., and R.S. Rogers Substituted thiazoles for the treatment of inflammation WO 9603392 A1 Chem. Abstr. 125 1996 33628
27. J.-L. Mao, X.-K. Ran, J.-Z. Tian, B. Jiao, H.-L. Zhou, L. Chen, and Z.-G. Wang Design, synthesis and biological evaluation of novel 4- hydroxybenzeneacrylic acid derivatives Bioorg. Med. Chem. Lett. 21 2011 1549 1553
28. X. Ran, J. Mao, H. Pang, L. Chen, B. Jiao, Preparation of 3-phenyl-2-(4-mesylphenyl)acrylates as cyclooxygenase-2 inhibitors for treatment of inflammation and pain, Faming Zhuanli Shenqing Gongkai Shuomingshu, Patent CN 1762994 (April 26, 2006); Chem. Abstr., 145, 2006, 62680.
29. D. Macdonald, A. Mastracchio, H. Perrier, D. Dube, M. Gallant, C. Li, L.A. Trimble, S. Day, N. Chauret, D.A. Nicoll-Griffith, J.M. Silva, Z. Huang, F. Laliberte, S. Liu, D. Ethier, D. Pon, E. Muise, L. Boulet, C.C. Chan, A. Styhler, S. Charleson, J. Mancini, P. Masson, D. Claveau, D. Nicholson, M. Turner, R.N. Young, and Y. Girard Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor Bioorg. Med. Chem. Lett. 15 2005 5241 5246
30. F. Wang, S. Li, and W. Feng Anti-inflammatory structure-activity relationships of a new series of open-loop COX-2 inhibitors derived from rofecoxib Beijing Huagong Daxue Xuebao, Ziran Kexueban 31 2004 84 87 Chem. Abstr. 142 (2005) 385056
31. T. Rosen The Perkin reaction B. Trost, I. Fleming, Comprehensive Organic Synthesis vol. 2 1991 Pergamon Press Oxford 395 408
32. U. Dhagat, S. Endo, R. Sumii, A. Hara, and O. El-Kabbani Selectivity determinants of inhibitor binding to human 20α-hydroxysteroid dehydrogenase: crystal structure of the enzyme in ternary complex with coenzyme and the potent inhibitor 3,5-dichlorosalicylic acid J. Med. Chem. 51 2008 4844 4848
33. A.L. Lovering, J.P. Ride, C.M. Bunce, J.C. Desmond, S.M. Cummings, and S.A. White Crystal structures of prostaglandin D2 11-ketoreductase (AKR1C3) in complex with the nonsteroidal anti-inflammatory drugs flufenamic acid and indomethacin Cancer Res. 64 2004 1802 1810
34. M. McGann FRED pose prediction and virtual screening accuracy J. Chem. Inf. Model. 51 2011 578 596
35. P. Brožič, T. Šmuc, S. Gobec, and T. Lanišnik-Rižner Phytoestrogens as inhibitors of the human progesterone metabolizing enzyme AKR1C1 Mol. Cell. Endocrinol. 259 2006 30 42